Ofatumumab is first self-administered, targeted B-cell treatment for relapsing MS. The first self-administered, targeted B-cell treatment for relapsing multiple sclerosis (EM) received FDA approval


NB Ciencia

organización de contratos de investigación

terapia con células madre